BioCentury
ARTICLE | Finance

Design debuts with $45M series A, portfolio against repeat expansions

March 21, 2020 12:42 AM UTC

Design Therapeutics emerged from stealth Friday with a $45 million series A and a portfolio of bifunctional small molecules to treat degenerative disorders caused by nucleotide repeat expansions, starting with Friedreich's ataxia.

SR One led the untranched round with participation from Cormorant Asset Management, Quan Capital and WestRiver Group...

BCIQ Company Profiles

Triplet Therapeutics Inc.